Qva149 Significantly Lowers The Rate And Risk Of Moderate Or Severe COPD Exacerbation Versus Salmeterol/fluticasone In Patients With Moderate To Severe COPD: The Lantern Study

被引：0
|
作者：
Zhong, N. [1 ]
Wang, C. [2 ]
Zhou, X. [3 ]
Zhang, N. [1 ]
Patalano, F. [4 ]
Humphries, M. [5 ]
Wang, L. [5 ]
Banerji, D. [6 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China
[2] Third Mil Med Univ, Inst Resp Dis, Xin Qiao Hosp, Chongqing, Peoples R China
[3] Third Mil Med Univ, Southwest Hosp, Dept Resp Med, Chongqing, Peoples R China
[4] Novartis Pharma AG, Basel, Switzerland
[5] Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China
[6] Novartis Pharmaceut, E Hanover, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3978
引用
收藏
页数：3
相关论文
共 50 条
  • [31] N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD
    Pela, R
    Calcagni, AM
    Subiaco, S
    Isidori, P
    Tubaldi, A
    Sanguinetti, CM
    RESPIRATION, 1999, 66 (06) : 495 - 500
  • [32] EFFICACY AND SAFETY OF IND/GLY COMPARED WITH SALMETEROL/FLUTICASONE COMBINATION IN CHINESE PATIENTS WITH MODERATE-TO-SEVERE COPD: A SUBGROUP ANALYSIS FROM THE LANTERN STUDY
    Larbig, Michael
    Zhong, Nanshan
    Wang, Changzheng
    Zhou, Xiangdong
    Zhang, Nuofu
    Patalano, Francesco
    Humphries, Michael
    Wang, Linda
    Banerji, Donald
    RESPIROLOGY, 2015, 20 : 45 - 45
  • [33] Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)
    Henrik Watz
    Claudia Mailänder
    Monika Baier
    Anne Kirsten
    BMC Pulmonary Medicine, 16
  • [34] Qva149 Demonstrates Superior Improvements In Health Status, As Measured By Sgrq, Compared With Placebo In Patients With Moderate-To-Severe COPD: The Flight2 Study
    Jones, P. W.
    Ayers, T.
    FowlerTaylor, A.
    Larbig, M.
    Thach, C.
    Maitra, S.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [35] Efficacy of Indacaterol/Glycopyrronium Versus Salmeterol/Fluticasone by Gender in Patients with Moderate-to-Very severe COPD: Analyses from the FLAME Study
    Wedzicha, J. A.
    Singh, D.
    Kostikas, K.
    Shen, S.
    Fogel, R.
    Fucile, S.
    Goyal, P.
    Mezzi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [36] Qva149 Shows Rapid Onset Of Bronchodilation Versus Placebo And Its Mono-Components In Patients With Moderate To Severe COPD: Pooled Data From The Flight Studies
    Banerji, D.
    FowlerTaylor, A.
    Ayers, T.
    Thach, C.
    Patalano, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [37] Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)
    Watz, Henrik
    Mailaender, Claudia
    Baier, Monika
    Kirsten, Anne
    BMC PULMONARY MEDICINE, 2016, 16
  • [38] Superiority of "triple'' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD
    Singh, D.
    Brooks, J.
    Hagan, G.
    Cahn, A.
    O'Connor, B. J.
    THORAX, 2008, 63 (07) : 592 - 598
  • [39] Cardiovascular Safety of QVA149 in Patients With Moderate-to-Severe COPD: Pooled Analysis of FLIGHT1 and FLIGHT2 Clinical Studies
    Fogel, Robert
    Ayers, Tim
    Banerji, Donald
    Maitra, Samopriyo
    Schubert-Tennigkeit, Agnes Annette
    CHEST, 2015, 148 (04)
  • [40] ASSESSING DIRECT SWITCH TO INDACATEROL/GLYCOPYRRONIUM FROM SALMETEROL/FLUTICASONE IN MODERATE TO SEVERE SYMPTOMATIC COPD PATIENTS: THE FLASH STUDY
    Frith, Peter
    Ashmawi, Samiha
    Krishnamurthy, Srikanth
    Diaz, Dina
    Gurgun, Alev
    Hours-Zesiger, Peggy
    Hristoskova, Sashka
    Pilipovic, Virginia
    RESPIROLOGY, 2017, 22 : 70 - 70
12345